Kameel D. Farag - 01 Nov 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role: Interim CFO
Signature: /s/ Abizer Gaslightwala, Attorney-in-Fact
Issuer symbol: AKTX
Transactions as of: 01 Nov 2025
Net transactions value: +$43,964
Form type: 4
Filing time: 04 Nov 2025, 17:00:02 UTC
Previous filing: 24 Oct 2025
Next filing: 18 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Farag Kameel D.	Interim CFO	C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA	/s/ Abizer Gaslightwala, Attorney-in-Fact	04 Nov 2025	0002093620

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKTX	American Depositary Shares representing Ordinary Shares	Award	$24,000	+32,000		$0.7500	32,000	01 Nov 2025	Direct	F1, F2
transaction	AKTX	American Depositary Shares representing Ordinary Shares	Award	$19,964	+26,619		$0.7500	26,619	01 Nov 2025	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer
F2	These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on January 1, 2026.
F3	These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on February 15, 2026.